
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : MGC Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Details : The agreement is for the distribution in key European territories and the UK for CannEpil®, used to treat Drug Resistant Epilepsy, and CogniCann®, used to treat patients with Dementia and Alzheimer's disease.
Product Name : CannEpil
Product Type : Controlled Substance
Upfront Cash : Undisclosed
April 05, 2022
Lead Product(s) : Cannabidiol,Tetrahydrocannabinol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : MGC Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
